Vaccination studies are ongoing to stop the coronavirus pandemic. Human testing of vaccines that work in animals started quickly. Tests and reviews are ongoing to get the long-term results of these vaccines. According to a new report, researchers from the University of Pittsburgh Medical School, one of the prestigious medical faculties of the USA, have developed a new vaccine against coronavirus. The developed vaccine was able to produce SARS-CoV-2 antibodies, which were considered sufficient to neutralize the virus in mouse tests. Andrea Gambotto, of the University of Pittsburgh Medical School, who played a role in the development of the coronavirus vaccine, said that they are experienced with SARS in 2003 and MERS in 2014. Gambotto stated that the study of these two viruses is important for triggering immunity in a protein called spike protein. The new coronavirus vaccine, called PittCoVacc, is applied with a finger-tip sized patch. The researchers explained that in developing the vaccine, they have taken a more radical approach based on viral protein fragments, unlike other vaccine studies based on mRNA. Scientists used an approach that they called the micro needle array to increase the strength of the vaccine. This micro needle array is a finger-sized patch of 400 small needles that allow spike protein pieces to be delivered to the skin. Needles made entirely of sugar and protein dissolve after some time after the vaccine is applied to the skin. The new coronavirus vaccine, which works with the system called micro needle array, can also be scaled at high rates. The layers that make up the pieces of protein used in the vaccine can be duplicated when the efficiency of the vaccine is desired to be increased. Room temperature is sufficient to maintain the vaccine developed by scientists from the University of Pittsburgh School of Medicine. The vaccine remains intact at room temperature, making it easy to transport and store the vaccine after production. In tests of the new coronavirus vaccine, called PittCoVac, in mice, antibodies against the SARS-CoV-2 virus were formed for two weeks after the vaccine was administered. However, the animals have not been followed for a long time yet. Researchers say that animals are being followed up for a year in SARS and MERS vaccine studies. The rapid spread of the coronavirus pandemic in the world causes the development of the vaccine to progress faster. That’s why researchers from the University of Pittsburgh Medical School are waiting for permission to perform their first clinical test on humans in the next few months.
